Search
Now showing items 1-1 of 1
Exploring Multivalency and Chemical Modifications in the Development of Anti-PD-L1 Peptide Inhibitors for Cancer Immunotherapy
(2023)
The PD-1/PD-L1 immune checkpoint axis is one of the most common pathways exploited by cancers to evade immune surveillance. Many cancers overexpress PD-L1 (programmed cell death ligand 1) on their surface through which ...